Pacira BioSciences reports preliminary 2022 revenue of $666.8M, up 23.1% YoY

Pacira BioSciences, Inc.

2022-FY EPS reported $0.34 revenue$666,823,000

EXPAREL net sales $536.9M in 2022 vs $506.5M in 2021; Q4 2022 sales $138.0M, roughly flat vs prior Q4.
ZILRETTA net sales $105.5M in 2022 vs $12.7M in 2021 (acquired Nov 2021); Q4 2022 sales $28.0M.
Adjusted EPS expected at least $2.50 for 2022, marking ninth consecutive year of positive adjusted earnings.
Prepaid $50M on Term Loan B in Dec 2022; plans another significant prepayment in 2023.
Management cites strong balance sheet, durable cash flows, and outperformance vs surgical market.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pacira BioSciences, Inc. reported 2022 results: EPS adjusted earnings per share of at least $2.50.

Period: 2022
EPS: adjusted earnings per share of at least $2.50
Result: preliminary results

Exact text from the filing

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $666.8 million for 2022, compared with $541.5 million for 2021, representing an increase of 23.1 percent.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pacira BioSciences, Inc. reported 2022 results: EPS adjusted earnings per share of at least $2.50.

Period: 2022
EPS: adjusted earnings per share of at least $2.50
Result: preliminary results

Exact text from the filing

We ended the year with a strong balance sheet and expect to report adjusted earnings per share of at least $2.50 for 2022, marking our ninth consecutive year of positive adjusted earnings.

View on SEC.gov

Browse all earnings releases →

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001396814-23-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.